8
May
2023

Creating a New Class of Medicines: John Maraganore on The Long Run

Today’s guest on The Long Run is John Maraganore.

John Maraganore

John is best known as the former CEO of Alnylam Pharmaceuticals, the RNA interference drug developer. He spent 19 years there as CEO, before stepping down at the end of 2021. Alnylam figured out how to make a new therapeutic modality — gene-silencing with double-stranded oligonucleotide therapies.

Alnylam’s technology has now been translated into five marketed medicines. The company has more than 2,000 employees, and a market value that exceeds $26 billion.

Since leaving Alnylam, John has taken on a sort of senior statesman role in biotech – wired in with investors such as Arch Venture Partners, Atlas Venture, RTW Investments and Blackstone. He serves on a variety of public company boards, such as Agios Pharmaceuticals, Beam Therapeutics, Kymera Therapeutics and Takeda Pharmaceuticals. He advises a number of young scientific entrepreneurs. He seems to be everywhere there’s some cool translational science work to be done. I joke with him that he’s the Dos Equis Man of biotech – the beer commercial that features the supposedly most interesting man in the world.

This conversation was recorded live in Seattle on Apr. 25 in front of an audience at the Life Science Innovation Northwest conference. We talk about John’s early life, key early career experiences, a few major events at Alnylam, and a bit of his views on science and policy.

And now for a word from the sponsor of The Long Run.

Tired of spending hours searching for the exact research products and services you need? Scientist.com is here to help. Their award-winning digital platform makes it easy to find and purchase life science reagents, lab supplies and custom research services from thousands of global laboratories. Scientist.com helps you outsource everything but the genius! 

Save time and money and focus on what really matters, your groundbreaking ideas. 

Learn more at:

Scientist.com/LongRun

Now, please join me and John Maraganore on The Long Run.

You may also like

A New Outlook on Life With Sickle Cell Disease: Jimi Olaghere on The Long Run
SynBio and AI for Discovery: David Younger and Randolph Lopez on The Long Run
Investing in Biotech & Healthcare Delivery: Vineeta Agarwala on The Long Run
New Tools & Techniques for Biology: David Liu on The Long Run